A Study to Assess Intraocular Pressure and Ocular Safety of the Beta-3 Agonist Mirabegron in Research Subjects

Summary

The purpose of this study is to assess the affect of mirabegron on intraocular pressure (IOP) in healthy subjects.

Timeline

Start

2010-11

Primary completion

2011-02

Completion

2011-02

Outcome

Met primary endpoint

paper For the primary endpoint, mirabegron was noninferior to placebo, based on the prespecified limit of 1.5 mmHg. PMID 23586728 ↗

Publications

• Novack GD, Lewis RA, Vogel R, Sheth N, Swearingen D, Rasmussen S, Hantsbarger G, Martin NE. Randomized, double-masked, placebo-controlled study to assess the ocular safety of mirabegron in healthy volunteers. J Ocul Pharmacol Ther. 2013 Sep;29(7):674-80. doi: 10.1089/jop.2012.0254. Epub 2013 Apr 15.

Drugs

Indications

No indication recorded.